Prime Medicine (PRME) Secures First Regulatory Clearance for PM577a in Wilson Disease

Prime Medicine (PRME) announced on June 18, 2026, it received its first regulatory clearance to advance PM577a, a novel Prime Editing candidate, into clinical trials. This approval targets the treatment of Wilson Disease, a genetic disorder, marking a significant step for the company's therapeutic pipeline. The clearance enables Prime Medicine to initiate the first-in-human study for PM577a. Wilson Disease causes copper accumulation in organs, leading to severe liver, neurological, and psychiatric symptoms. PM577a aims to address the underlying genetic cause of the disease. The specific regulatory body granting the clearance was not detailed in the announcement.